ZUG, Switzerland, January 6, 2025 – Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The phase 2 ACUITY trial met its primary safety endpoint ...
A nationwide cohort study of more than 4 million adults showed that people with allergic diseases were nearly one third more likely to develop optic neuritis than those without such conditions, with ...
For most optometrists, visual electrophysiology testing has been considered the last test to turn to when a patient presents with unexplained vision loss. However, the increased accessibility of ...
Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential ...
Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results